Showing results (121-130 of 260) with videos related to
Sort By:
Pageof 26
Cellular and Molecular Gastroenterology and Hepatology|June 17, 2022
Deletion of Lactate Dehydrogenase-A Impairs Oncogene-Induced Mouse Hepatocellular Carcinoma DevelopmentMarina Serra, Mario Di Matteo, Jens Serneels, et al.Journal of Cellular and Molecular Medicine|March 28, 2008
Thymoquinone reduces mouse colon tumor cell invasion and inhibits tumor growth in murine colon cancer modelsHala Gali-Muhtasib, Matthias Ocker, Doerthe Kuester, et al.European Journal of Clinical Investigation|June 20, 2014
Clofarabine/cyclophosphamide for debulking before stem cell transplantationWerner Rabitsch, Alexandra Böhm, Marija Bojic, et al.European Journal of Cancer (Oxford, England : 1990)|May 22, 2021
Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: Results of a randomised phase II AGMT trialFelix Keil, Maximilian Hartl, Gabriela Altorjai, et al.American Journal of Hematology|June 1, 2024
BRD4 degraders may effectively counteract therapeutic resistance of leukemic stem cells in AML and ALLKarin Bauer, Alexander Hauswirth, Karoline V Gleixner, et al.Aktuelle Urologie|April 20, 2017
[Clinical and pathological prognostic factors for the long-term survival of patients with pT1 renal cell carcinoma]Johannes Breyer, Wolfgang Otto, Eva Maria Lausenmeyer, et al.Oncotarget|December 25, 2014
SKP2 cooperates with N-Ras or AKT to induce liver tumor development in miceSalvatore Delogu, Chunmei Wang, Antonio Cigliano, et al.Hepatology (Baltimore, Md.)|January 25, 2022
Therapeutic efficacy of FASN inhibition in preclinical models of HCCHaichuan Wang, Yi Zhou, Hongwei Xu, et al.Bladder Cancer (Amsterdam, Netherlands)|August 22, 2017
Increased Proliferation as Independent Predictor of Disease Recurrence in Initial Stage pTa Urothelial Bladder CancerJohannes Breyer, Sanzhar Shalekenov, Atiqullah Aziz, et al.Wiener Klinische Wochenschrift|December 14, 2018
Correction to: Ruxolitinib therapy formyelofibrosis in Austria : Consensus on therapy managementMaria-Theresa Krauth, Sonja Burgstaller, Veronika Buxhofer-Ausch, et al.Pageof 26